- Home
- IACO vs XFOR Comparison
IACO vs XFOR Comparison
Compare IACO & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$2.80
Company Overview
Basic Information| Metric | IACO | XFOR |
|---|---|---|
| Founded | 2025 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 437.1M | 377.3M |
| IPO Year | 2025 | 2017 |
Fundamental Metrics
Financial Performance| Metric | IACO | XFOR |
|---|---|---|
| Price | $9.99 | $2.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $11.60 |
| AVG Volume (30 Days) | 59.1K | ★ 1.1M |
| Earning Date | N/A | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 150.00 |
| 52 Week Low | $9.91 | $2.70 |
| 52 Week High | $10.01 | $4.83 |
Technical Indicators
Market Signals| Indicator | IACO | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 55.83 | 27.23 |
| Support Level | $9.97 | N/A |
| Resistance Level | $10.01 | $4.40 |
| Average True Range (ATR) | 0.00 | 0.17 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 0.00 | 10.16 |
Price Performance
Historical Comparison IACO
XFOR
About IACO Idea Acquisition Corp. Class A Ordinary Shares
Idea Acquisition Corp is a blank check company.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.